Index S&P 500
P/E 16.55
EPS (ttm) 1.38
Insider Own 0.06%
Shs Outstand 5.68B
Perf Week 2.47%
Market Cap 129.80B
Forward P/E 7.40
EPS next Y 3.08
Insider Trans 0.50%
Shs Float 5.68B
Perf Month 3.58%
Income 7.87B
PEG -
EPS next Q 0.56
Inst Own 67.16%
Short Float 2.03%
Perf Quarter -10.58%
Sales 62.46B
P/S 2.08
EPS this Y -3.18%
Inst Trans -1.56%
Short Ratio 2.13
Perf Half Y -12.83%
Book/sh 15.89
P/B 1.44
EPS next Y 2.40%
ROA 3.67%
Short Interest 115.16M
Perf Year -19.56%
Cash/sh 3.05
P/C 7.50
EPS next 5Y -0.28%
ROE 8.62%
52W Range 20.92 - 31.54
Perf YTD -13.95%
Dividend Est. 1.71 (7.47% )
P/FCF 11.57
EPS past 5Y -13.25%
ROI 5.32%
52W High -27.62%
Beta 0.51
Dividend TTM 1.70 (7.45% )
Quick Ratio 0.96
Sales past 5Y 17.19%
Gross Margin 66.93%
52W Low 9.16%
ATR (14) 0.68
Dividend Ex-Date May 09, 2025
Current Ratio 1.26
EPS Y/Y TTM 2770.58%
Oper. Margin 27.53%
RSI (14) 47.17
Volatility 2.97% 2.66%
Employees 81000
Debt/Eq 0.69
Sales Y/Y TTM 13.38%
Profit Margin 12.59%
Recom 2.38
Target Price 28.26
Option/Short Yes / Yes
LT Debt/Eq 0.64
EPS Q/Q -5.13%
Payout 119.94%
Rel Volume 0.69
Prev Close 22.60
Sales Surprise -1.47%
EPS Surprise 38.22%
Sales Q/Q -7.82%
Earnings Apr 29 BMO
Avg Volume 54.16M
Price 22.83
SMA20 -0.79%
SMA50 -4.54%
SMA200 -14.09%
Trades
Volume 37,547,982
Change 1.02%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-22-25 Initiated
Cantor Fitzgerald
Neutral
$24
Dec-10-24 Resumed
BofA Securities
Neutral
$29
Nov-15-24 Initiated
Wolfe Research
Underperform
$25
Oct-25-24 Resumed
Citigroup
Neutral
$30
Oct-17-24 Initiated
Bernstein
Mkt Perform
$32
Aug-07-24 Upgrade
Daiwa Securities
Neutral → Outperform
Mar-22-24 Downgrade
Argus
Buy → Hold
Feb-23-24 Initiated
Guggenheim
Buy
$36
Jan-04-24 Downgrade
TD Cowen
Outperform → Market Perform
$32
Oct-20-23 Resumed
UBS
Neutral
$36 → $34
Oct-16-23 Upgrade
Jefferies
Hold → Buy
$38 → $39
Jul-17-23 Reiterated
JP Morgan
Neutral
$45 → $41
Jul-14-23 Initiated
HSBC Securities
Buy
$50
Jun-29-23 Downgrade
Credit Suisse
Outperform → Neutral
$47 → $40
May-11-23 Downgrade
Daiwa Securities
Outperform → Neutral
$38
Mar-06-23 Initiated
Jefferies
Hold
$43
Feb-07-23 Upgrade
Daiwa Securities
Neutral → Outperform
$51
Jan-26-23 Downgrade
UBS
Buy → Neutral
$55 → $47
Jan-17-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$54 → $50
Jan-04-23 Downgrade
BofA Securities
Buy → Neutral
$60
Show Previous Ratings
Today 12:05PM
May-16-25 11:31AM
09:00AM
04:49AM
May-15-25 04:43PM
11:20AM
Loading…
11:20AM
(The Wall Street Journal)
08:36AM
08:27AM
May-14-25 06:05PM
02:34PM
10:15AM
07:46AM
04:32AM
(Associated Press Finance)
03:40AM
03:40AM
03:40AM
Loading…
03:40AM
May-13-25 05:07PM
11:40AM
11:18AM
10:37AM
09:40AM
09:22AM
09:00AM
07:36AM
May-12-25 08:59PM
07:20PM
04:17PM
03:50PM
02:58PM
02:35PM
02:30PM
Loading…
02:30PM
12:34PM
10:44AM
09:37AM
09:25AM
09:09AM
08:50AM
07:55AM
07:49AM
07:38AM
07:33AM
(The Wall Street Journal)
04:51AM
04:28AM
May-10-25 05:39AM
04:17AM
May-09-25 12:44PM
09:55AM
08:23AM
08:12AM
May-08-25 10:01PM
11:50AM
09:55AM
05:45AM
04:00AM
12:30AM
May-07-25 04:51PM
02:54PM
01:50PM
11:35AM
10:32AM
05:30AM
(The Wall Street Journal)
May-06-25 06:15PM
01:25PM
09:54AM
04:33AM
May-05-25 02:49PM
09:00AM
08:22AM
08:10AM
08:00AM
07:30AM
May-04-25 11:20AM
May-03-25 08:30AM
04:51AM
01:26AM
May-02-25 01:19PM
10:00AM
09:01AM
08:59AM
07:30AM
03:51AM
03:03AM
May-01-25 09:05PM
01:30PM
12:34PM
12:06PM
11:51AM
11:22AM
08:57AM
(Thomson Reuters StreetEvents)
08:54AM
08:45AM
08:40AM
07:15AM
04:50AM
04:15AM
03:17AM
Apr-30-25 04:27PM
(Investor's Business Daily)
09:10AM
09:08AM
07:05AM
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Dolsten Mikael Former Officer May 05 '25 Proposed Sale 23.87 55,000 1,312,736 May 05 04:45 PM DAMICO JENNIFER B. SVP & Controller Mar 04 '25 Sale 25.93 2,500 64,825 11,850 Mar 06 01:57 PM DAMICO JENNIFER B. SVP & Controller Feb 27 '25 Option Exercise 31.31 22,416 701,845 31,063 Mar 03 05:39 PM SUSMAN SALLY Executive Vice President Feb 27 '25 Option Exercise 31.31 85,182 2,667,048 250,866 Mar 03 05:38 PM SAHNI PAYAL Executive Vice President Feb 27 '25 Option Exercise 31.31 19,054 596,581 44,242 Mar 03 05:38 PM McDermott Michael Executive Vice President Feb 27 '25 Option Exercise 31.31 48,419 1,515,999 122,413 Mar 03 05:37 PM LANKLER DOUGLAS M Executive Vice President Feb 27 '25 Option Exercise 31.31 156,914 4,912,977 309,790 Mar 03 05:37 PM Fonseca Lidia Executive Vice President Feb 27 '25 Option Exercise 31.31 72,629 2,274,014 111,534 Mar 03 05:36 PM BOURLA ALBERT Chairman & CEO Feb 27 '25 Option Exercise 31.31 582,823 18,248,188 931,744 Mar 03 05:36 PM McDermott Michael Executive Vice President Feb 22 '25 Option Exercise 30.17 11,125 335,641 87,636 Feb 25 07:38 PM DAMICO JENNIFER B. SVP & Controller Feb 22 '25 Option Exercise 30.17 8,741 263,716 17,602 Feb 25 07:38 PM BOURLA ALBERT Chairman & CEO Feb 22 '25 Option Exercise 30.17 238,399 7,192,498 570,436 Feb 25 07:06 PM LANKLER DOUGLAS M Executive Vice President Feb 22 '25 Option Exercise 30.17 85,824 2,589,310 232,775 Feb 25 07:05 PM SAHNI PAYAL Executive Vice President Feb 22 '25 Option Exercise 30.17 12,714 383,581 37,099 Feb 25 07:04 PM SUSMAN SALLY Executive Vice President Feb 22 '25 Option Exercise 30.17 63,573 1,917,997 225,184 Feb 25 07:02 PM BOSHOFF CHRISTOFFEL President, R&D Feb 22 '25 Option Exercise 30.17 8,741 263,716 159,085 Feb 25 06:58 PM BLAYLOCK RONALD E Director Feb 13 '25 Buy 25.65 19,457 499,072 27,707 Feb 14 05:16 PM Gottlieb Scott Director Oct 30 '24 Buy 28.24 1,000 28,240 10,000 Oct 31 04:06 PM DAMICO JENNIFER B. SVP & Controller Aug 13 '24 Sale 28.66 5,154 147,714 8,582 Aug 14 03:47 PM